FR2448348A1 - Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe - Google Patents

Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe

Info

Publication number
FR2448348A1
FR2448348A1 FR8003015A FR8003015A FR2448348A1 FR 2448348 A1 FR2448348 A1 FR 2448348A1 FR 8003015 A FR8003015 A FR 8003015A FR 8003015 A FR8003015 A FR 8003015A FR 2448348 A1 FR2448348 A1 FR 2448348A1
Authority
FR
France
Prior art keywords
carnitine
acyl
pharmaceutical composition
perturbic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR8003015A
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT7947976A external-priority patent/IT1206954B/it
Priority claimed from IT50795/79A external-priority patent/IT1164062B/it
Application filed by Individual filed Critical Individual
Publication of FR2448348A1 publication Critical patent/FR2448348A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR8003015A 1979-02-12 1980-02-12 Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe Pending FR2448348A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT7947976A IT1206954B (it) 1979-02-12 1979-02-12 Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT50795/79A IT1164062B (it) 1979-11-09 1979-11-09 Composizione farmaceutica comprendente una acil-carnitina per il trattamento del rallentato metabolismo cerebrale

Publications (1)

Publication Number Publication Date
FR2448348A1 true FR2448348A1 (fr) 1980-09-05

Family

ID=26329263

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8003015A Pending FR2448348A1 (fr) 1979-02-12 1980-02-12 Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe

Country Status (8)

Country Link
US (1) US4346107A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU535518B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE881680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH641673A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3005208A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2448348A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2046593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8000768A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
EP0256999A3 (en) * 1986-08-04 1989-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine in the therapeutical treatment of peripheral neuropathies
EP0225856A3 (en) * 1985-10-14 1989-06-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine for the therapeutical treatment of shock conditions
EP0207011A3 (en) * 1985-06-11 1989-11-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of some alkanoyl l-carnitines for the therapeutical treatment of idiopathic and induced parkinsonism
EP0253777A3 (en) * 1986-07-04 1990-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine in the treatment of toxic effects induced by the inhalation of halotane and other halogen-containing general anesthetics
EP0498144A1 (en) * 1991-01-04 1992-08-12 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of acetyl L-carnitine in the therapeutic treatment of coma
WO1999066914A3 (en) * 1998-06-25 2000-04-06 Sigma Tau Healthscience Spa Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198434B (it) * 1981-01-06 1988-12-21 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
IT1284650B1 (it) * 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
US20090253781A1 (en) * 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
WO1998041201A1 (en) * 1997-03-17 1998-09-24 Btg International Limited Therapeutic compositions
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
IT1291127B1 (it) 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5869528A (en) * 1997-07-22 1999-02-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutical method for the treatment of attention-deficit/hyperactive disorders
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1292294B1 (en) * 2000-05-01 2009-03-18 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
DE60216090T2 (de) * 2001-05-29 2007-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
US8894973B2 (en) * 2002-02-07 2014-11-25 Jay W. Pettegrew Method and system for differential diagnosis of chronic schizophrenia and chronic alcoholism
US20100010336A1 (en) * 2002-02-07 2010-01-14 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (adhd), autism, and schizophrenia
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
MXPA04007506A (es) * 2002-02-07 2004-11-10 Sigma Tau Ind Farmaceuti Carnitina en tratamiento de depresion geriartrica.
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
CN1795198B (zh) * 2003-05-29 2011-08-17 杰伊·W·佩特格尤 对神经精神疾病进行医学成像所用的甘油磷酸胆碱及其衍生物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
USD516320S1 (en) 2004-07-15 2006-03-07 The Procter & Gamble Company Surface pattern of a paper product
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
WO2006020179A2 (en) * 2004-07-20 2006-02-23 Ketocytonyx Inc. Oligomeric ketone compounds
WO2006012490A2 (en) * 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
WO2006098767A2 (en) * 2004-09-21 2006-09-21 Ketocytonyx Inc. Treatment of adhd
ES2574557T3 (es) * 2004-09-21 2016-06-20 Btg International Limited Miméticos dopaminérgicos
USD510665S1 (en) 2004-09-29 2005-10-18 The Procter & Gamble Company Surface pattern for an embossed paper product
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
EP2468273A3 (en) * 2005-06-20 2012-07-11 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
ES2697504T3 (es) 2006-04-03 2019-01-24 Accera Inc Uso de compuestos cetogénicos para el tratamiento de la alteración de la memoria asociada a la edad
ES2556535T3 (es) 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
WO2010003114A1 (en) * 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
CA2801281C (en) * 2010-06-16 2018-07-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물
IT202100020729A1 (it) 2021-08-02 2023-02-02 Univ Degli Studi Di Napoli Federico Ii Preparazione combinata per il trattamento della malattia di Pompe

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1573430A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1967-07-03 1969-07-04
FR2209545A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-12-07 1974-07-05 Otsuka Pharma Co Ltd
FR2388556A1 (fr) * 1977-04-29 1978-11-24 Sigma Tau Ind Farmaceuti Application therapeutique de l'acetyl-carnitine-d,1 et d'autres derives acyliques de la carnitine-d,1
FR2407717A1 (fr) * 1977-11-03 1979-06-01 Sigma Tau Ind Farmaceuti Usage therapeutique nouveau de l'acetyl-1-carnitine
FR2414914A1 (fr) * 1978-01-18 1979-08-17 Sigma Tau Ind Farmaceuti Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine
FR2425855A1 (fr) * 1978-05-15 1979-12-14 Cavazza Claudio Application des acyl-carnitines a un procede therapeutique de traitement de patients uremiques chroniques en traitement hemodialytique periodique et composition liquide de dialyse pour la mise en oeuvre d'un tel procede

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1256162A (en) * 1968-08-16 1971-12-08 Braun Fa B Improvements in and relating to liquid products for intravenous administration
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1573430A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1967-07-03 1969-07-04
FR2209545A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-12-07 1974-07-05 Otsuka Pharma Co Ltd
FR2388556A1 (fr) * 1977-04-29 1978-11-24 Sigma Tau Ind Farmaceuti Application therapeutique de l'acetyl-carnitine-d,1 et d'autres derives acyliques de la carnitine-d,1
FR2407717A1 (fr) * 1977-11-03 1979-06-01 Sigma Tau Ind Farmaceuti Usage therapeutique nouveau de l'acetyl-1-carnitine
FR2414914A1 (fr) * 1978-01-18 1979-08-17 Sigma Tau Ind Farmaceuti Utilisations therapeutiques nouvelles de l'acetyl-1-carnitine et d'autres derives acyles de la 1-carnitine
FR2425855A1 (fr) * 1978-05-15 1979-12-14 Cavazza Claudio Application des acyl-carnitines a un procede therapeutique de traitement de patients uremiques chroniques en traitement hemodialytique periodique et composition liquide de dialyse pour la mise en oeuvre d'un tel procede

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207011A3 (en) * 1985-06-11 1989-11-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of some alkanoyl l-carnitines for the therapeutical treatment of idiopathic and induced parkinsonism
EP0225856A3 (en) * 1985-10-14 1989-06-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine for the therapeutical treatment of shock conditions
EP0253777A3 (en) * 1986-07-04 1990-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine in the treatment of toxic effects induced by the inhalation of halotane and other halogen-containing general anesthetics
EP0256999A3 (en) * 1986-08-04 1989-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of acetyl l-carnitine in the therapeutical treatment of peripheral neuropathies
EP0288447A1 (en) * 1987-04-22 1988-10-26 Anders Hamberger Composition for the treatment of migraine, by influencing thenerve cells.
EP0498144A1 (en) * 1991-01-04 1992-08-12 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of acetyl L-carnitine in the therapeutic treatment of coma
WO1999066914A3 (en) * 1998-06-25 2000-04-06 Sigma Tau Healthscience Spa Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin

Also Published As

Publication number Publication date
US4346107A (en) 1982-08-24
AU535518B2 (en) 1984-03-29
AU5526780A (en) 1980-08-21
NL8000768A (nl) 1980-08-14
CH641673A5 (it) 1984-03-15
BE881680A (fr) 1980-05-30
GB2046593A (en) 1980-11-19
DE3005208C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-12-28
DE3005208A1 (de) 1980-08-21

Similar Documents

Publication Publication Date Title
FR2448348A1 (fr) Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
FR2503562B1 (fr) Conditionnement pharmaceutique pour le traitement des symptomes de menopause
FR2448347A1 (fr) Composition pharmaceutique comprenant une acyl-carnitine pour le traitement des maladies vasculaires peripheriques
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
BE894024A (fr) Procede de preparation de derives d'esters internes de gangliosides et compositions pharmaceutiques contenant ces derives
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
MA18939A1 (fr) Procede de preparation d'un agent pour le traitement de theilerioses
FR2404625A1 (fr) Nouveaux 4-aminocyclohexanols et composition pharmaceutique les contenant
AU8579282A (en) Enzyme preparation for treatment of liver and kidney disease
BE900563A (fr) Composition pharmaceutique pour le traitement d'etats d'insuffisance renale aigue.
TNSN98210A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethyle, procede pour leur preparation et compositions pharmaceutiques les contenant
BE854416A (fr) Compositions pharmaceutiques pour le traitement des symptomes de la menopause et leur procede d'utilisation
BE891583A (fr) Acides 5,5-azobis-salicylique et ses sels utiles notamment pour le traitement des affections inflammatoires de l'intestin.
BE891639A (fr) Compositions pharmaceutiques contenant de la gamma-butyro-betaine pour le traitement de syndromes provoques par une deficience en l-carnitine
GB1298047A (en) Therapeutic agent
FR2559668B1 (fr) Compositions pharmaceutiques pour le traitement du diabete et de maladies et defauts de fonctionnement du foie
ES2076623T3 (es) 3,4-dihidro-naftalinas sustituidas, su procedimiento de preparacion y medicamentos que las contienen.
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
OA08609A (fr) Composition pharmaceutique pour le traitement des infections bactériennes.